Fundraising Fox

Altay Therapeutics

YC W20

San Francisco, US · Founded 2019 · 6 employees · 3 known investors

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

Also known as Altay Therapeutics Inc

BiotechDigital HealthHealthtechMedical DevicesAI-powered Drug DiscoveryTherapeuticsDrug discoveryUnited States of AmericaAmerica / Canada

Founders & leadership· Y Combinator alumni (W20)

Altay Therapeutics was founded in 2019 by Ali Ozes and Osman Ozes.

AOAli Ozes
Ali OzesinFounder and CEOFounder of Altay Therapeutics, which develops small molecule inhibitors targeting transcription factors to treat facioscapulohumeral muscular dystrophy, cancer, and inflammatory conditions.
OOOsman Ozes
Osman OzesinFounder and Chief Scientific OfficerOsman Ozes has over 30 years of academic research experience and 10 years in industry, with expertise in fibrosis, cancer immunology, and inflammatory diseases. He previously directed research at Intermune, where he led biomarker discovery for Pirfenidone (Esbriet), an FDA-approved lung fibrosis treatment; as founder and Chief Scientific Officer of Altay Therapeutics, he developed a platform targeting transcription factors for drug development.

Investors · 3

Creative Destruction Lab (CDL)Toronto · $50K – $250K
Tachyon VenturesLos Angeles
Y CombinatorSan Francisco · $500K

Competitors · 3

by search overlap
Bioworld34 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Coya Therapeutics30 shared keywords
Alloy22 shared keywordsAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

Companies competing with Altay Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase I2023$275K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$399.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$299.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$299.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

SOLVE FSHD invests US$3 million in Altay Therapeuticsfinance.yahoo.com · Sep 2022

Frequently asked questions

What does Altay Therapeutics do?
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Who founded Altay Therapeutics?
Altay Therapeutics was founded by Ali Ozes, Osman Ozes in 2019.
Who are Altay Therapeutics's investors?
Altay Therapeutics's investors include Creative Destruction Lab (CDL), Tachyon Ventures, Y Combinator.
Where is Altay Therapeutics headquartered?
Altay Therapeutics is headquartered in San Francisco, US.